SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
I’ve written a lot about businesses that help build Tucson. I want to tell you a about an organization and group of Tucson leaders who are directly impacting Tucson’s leaders of tomorrow. Steve Pearl, ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback